How to prevent and deal with the side effects of hypertension while taking pazopanib

Pazopanib (Pazopanib) is an oral multi-target tyrosine kinase inhibitor mainly used to treat diseases such as advanced renal cell carcinoma and soft tissue sarcoma. Although pazopanib has shown good efficacy in tumor treatment, one of its common side effects is hypertension, which has a greater impact on patients' treatment safety and quality of life. Therefore, how to effectively prevent and treat hypertension caused by pazopanib has become an issue that must be focused on during clinical treatment. This article will elaborate on the occurrence mechanism, prevention strategies, monitoring methods and treatment measures of hypertension.

First, understanding the mechanism by which pazopanib causes hypertension is particularly critical for prevention and management. Pazopanib blocks tumor angiogenesis by inhibiting targets such as vascular endothelial growth factor receptor (VEGFR), thereby inhibiting tumor growth. However, the VEGF signaling pathway plays an important role in maintaining vascular endothelial function and regulating vascular tone. After inhibiting VEGFR, the vasodilation function is weakened, leading to an increase in peripheral vascular resistance and an increase in blood pressure. In addition, pazopanib may affect renal sodium and water metabolism, promote water and sodium retention, and further aggravate hypertension. Therefore, the incidence of hypertension is higher during medication, and is more common in the early stages of treatment.

The first step in preventing hypertension is a thorough evaluation of the patient. Before starting pazopanib treatment, the patient's past medical history should be understood in detail, especially whether there are underlying diseases such as hypertension, cardiovascular disease, and kidney disease. At the same time, it is recommended that patients measure their blood pressure before taking medication to ensure that their blood pressure is within a controllable range. For patients with existing hypertension, antihypertensive treatment needs to be optimized to achieve the ideal blood pressure target (usually below 140/90 mmHg) before starting pazopanib. For patients without a history of hypertension, they need to be informed of the possible risks of hypertension, and instructed to pay attention to changes in blood pressure and conduct self-monitoring.

Blood pressure monitoring during treatment is critical. It is recommended that patients measure their blood pressure daily during the initial period of medication (especially the first 4 weeks), and then adjust the monitoring frequency according to their condition, at least once a week. Patients should develop the habit of measuring blood pressure in a quiet state and record the blood pressure value for the doctor's reference. For home blood pressure monitoring, it is recommended to use a proven electronic blood pressure monitor and master the correct measurement method. In addition, doctors should also regularly monitor blood pressure and assess cardiovascular risks during outpatient reviews to detect blood pressure abnormalities in a timely manner.

Once blood pressure is found to be elevated, corresponding measures should be taken promptly. Patients with mild hypertension can be managed through lifestyle interventions such as salt-restricted diet, increased exercise, weight loss, and smoking cessation. At the same time, starting or adjusting antihypertensive medications can be considered. Commonly used antihypertensive drugs include calcium channel blockers, ACE inhibitors or ARBs, these drugs are safer and more effective when combined with pazopanib. For patients with moderate to severe hypertension or symptoms of hypertensive crisis, the antihypertensive regimen should be adjusted as soon as possible, pazopanib treatment should be suspended if necessary, and the medication should be resumed after blood pressure control is stable. If patients experience serious cardiovascular events, such as heart failure, stroke, etc., they should seek medical treatment immediately.

In addition, close communication between doctors and patients is indispensable when managing pazopanib-related hypertension. Patients should proactively report blood pressure changes and discomfort symptoms, and doctors should formulate individualized treatment plans based on the patient's specific conditions, taking into account both tumor treatment effects and cardiovascular safety. At the same time, patient education is also very important to let patients understand the risks of hypertension, enhance their awareness of self-management, and ensure timely medication and monitoring.

In conclusion, hypertension is a common and important side effect during pazopanib treatment. Through risk assessment before treatment, strict monitoring and timely intervention during treatment, hypertension can be effectively prevented and controlled, and patients' treatment safety and quality of life can be guaranteed. Scientific and reasonable hypertension management not only helps to reduce pazopanib discontinuation and dosage adjustments, but also optimizes the overall treatment effect and brings more benefits to patients. In the future, with the accumulation of clinical experience and the deepening of relevant research, prevention and treatment strategies for hypertension will be more perfect, providing safer and more personalized treatment guarantees for pazopanib patients.

References：https://www.votrient.com/